• 30 kwietnia, 2021
imsc-krakow

Przewidywanie ciężkości COVID-19

Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby 

Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or demise.

Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness threat issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 chance ratio (96.7% specificity).

The outcomes lay the groundwork for a brand new sort of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such info might information more practical therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely unwell sufferers.

Prognosis of COVID-19 is instantly completed by a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness threat issue rating primarily based upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.

imsc-krakow
imsc-krakow

Anti-IGF-IIR antibody

STJ96634 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IR antibody

STJ98158 100 µl
EUR 234
Description: Mouse monoclonal to IGF-IR.

Anti-IGF-IR antibody

STJ98159 100 µl
EUR 234
Description: Mouse monoclonal to IGF-IR.

Anti-IGF-IR antibody

STJ93647 200 µl
EUR 197
Description: IGF-IR is a protein encoded by the IGF1R gene which is approximately 154,7 kDa. IGF-IR is localised to the cell membrane. It is involved in apoptotic pathways, the GPCR pathway and ERK signalling. It is a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1. The activated protein is involved in cell growth and survival control and is also crucial for tumour transformation and survival of malignant cells. It is formed from two subunits, each of which is comprised of an extracellular alpha-subunit and a transmembrane beta-subunit with intracellular tyrosine kinase activity. IGF-IR is expressed in the nervous system, skin, pancreas, lung and muscle. Mutations in the IGF1R gene may result in insulin-like growth factor 1 resistance. STJ93647 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of IGF-IR protein.

Anti-IGF-IR antibody

STJ93648 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Anti-IGF-I antibody

STJ93653 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-I.

Anti-IGF-IIR antibody

STJ93654 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IIR antibody

STJ93655 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IIR.

Anti-IGF-IR antibody

STJ93656 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Anti-IGF-IR antibody

STJ93657 200 µl
EUR 197
Description: Rabbit polyclonal to IGF-IR.

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

anti-IGF-1R (Ab-1280)

LF-PA20229 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Ab-1346)

LF-PA20230 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Ab-1161)

LF-PA20231 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Phospho-Tyr1161)

LF-PA20233 100 ul
EUR 354
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1161)

Anti-Rat IGF-1 Antibody

5121-100
EUR 316

Anti-Rat IGF-1 Antibody

5121-30T
EUR 146

Human Salivary IGF(salivary IGF) ELISA Kit

QY-E05383 96T
EUR 361

Anti-IGF-1R (Teprotumumab), Human IgG1 Antibody

A2160-100 100 µg
EUR 510

IGF-1, human

RC216-12 1mg
EUR 376.25

IGF-BP3, human

RC216-12B3 5ug
EUR 104.38

IGF-1, Human

HY-P7018 10ug
EUR 108

IGF-2, Human

HY-P7019 100ug
EUR 360

IGF-BP3, Human

HY-P7020 10ug
EUR 234

IGF-BP5, Human

HY-P7021 50ug
EUR 601

Polyclonal Anti-Rat IGF-1 Antibody

APR00269G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Anti-Rat IGF-1 . This antibody is tested and proven to work in the following applications:

Anti-IGF-1R (Ab-1161) Antibody

A00070-1 100ul
EUR 397
Description: Rabbit Polyclonal IGF-1R (Ab-1161) Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

Anti-Phospho-IGF-IR (Y1346) antibody

STJ91187 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1346).

Anti-Phospho-IGF-IR (Y1161) antibody

STJ90298 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161).

Anti-Phospho-IGF-IIR (S2409) antibody

STJ90923 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IIR (S2409).

Anti-Phospho-IGF-IR (Y1161) antibody

STJ91026 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1161).

anti-IGF-1R (Ab-1165/1166)

LF-PA20232 100 ul
EUR 334
Description: Rabbit polyclonal to IGF-1R

anti-IGF-1R (Phospho-Tyr1165/Tyr1166)

LF-PA20234 100 ul
EUR 354
Description: Rabbit polyclonal to IGF-1R (Phospho-Tyr1165/Tyr1166)

IGF-II

PR15045CF 50 ug
EUR 278

Human [Arg6] IGF-II

GU020 20 µg
EUR 253

Human [Leu24] IGF-I

ZU020 20 µg
EUR 253

Human [Leu24] IGF-I

ZU100 100 µg
EUR 346

Human [Leu27]IGF-II

TU100 100 µg
EUR 346

Biotinyl Human IGF-I

AQU010 10 µg
EUR 253

Biotinyl Human IGF-I

AQU050 50 µg
EUR 346

Biotinyl Human IGF-I

AQU100 100 µg
EUR 531

Biotinyl Human IGF-I

AQU500 500 µg
EUR 1088

Human [Ala31] IGF-I

AIU020 20 µg
EUR 253

Human [Ala31] IGF-I

AIU100 100 µg
EUR 346

Human IGF-I Protein

abx060791-100ug 100 ug
EUR 467

Human [Leu60] IGF-I

ABU020 20 µg
EUR 253

Human [Leu60] IGF-I

ABU100 100 µg
EUR 346

Human IGF-1 LR3

SP-89927-100 100 ug
EUR 225

IGF-1, human recombinant

P1016-.02 20 µg
EUR 258
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

IGF-1, human recombinant

P1016-.1 100 µg
EUR 763
Description: Insulin-like growth factor I (IGF-1) is a polypeptide endocrine hormone structurally similar to insulin and is mainly produced in the liver when stimulated by growth hormone. IGF-1 is a growth factor that stimulates the proliferation of various cell types including muscle, bone, and cartilage tissue

IGF-II, human recombinant

P1017-.01 10 µg
EUR 161
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

IGF-II, human recombinant

P1017-.05 50 µg
EUR 313
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

IGF-II, human recombinant

P1017-1 1 mg
EUR 1998
Description: Insulin-like Growth Factor-II (IGF-II) is a polypeptide endocrine hormone structurally similar to insulin and belongs to insulin-like growth factor family.

rec IGF-I (human)

H-5555.0050 50.0µg
EUR 242
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0100 100.0µg
EUR 381
Description: CAS# [67763-96-6]

rec IGF-I (human)

H-5555.0500 0.5mg
EUR 1434
Description: CAS# [67763-96-6]

IGF-I, human recombinant

4119-100
EUR 175

IGF-I, human recombinant

4119-1000
EUR 343

IGF-I, human recombinant

4119-10MG
EUR 1529

IGF-I, human recombinant

4119-1G
EUR 41157

IGF-I, human recombinant

4119-20MG
EUR 2328

IGF-I, human recombinant

4119-5000
EUR 958

IGF-I, human recombinant

4119-50MG
EUR 4220

IGF-II, human recombinant

4122-10
EUR 137

IGF-II, human recombinant

4122-1000
EUR 1572

IGF-II, human recombinant

4122-50
EUR 256

IGF-BP1, human recombinant

4717-100
EUR 620

IGF-BP1, human recombinant

4717-1000
EUR 3149

IGF-BP1, human recombinant

4717-25
EUR 256

IGF-BP3, human recombinant

4720-100
EUR 620

IGF-BP3, human recombinant

4720-1000
EUR 3149

IGF-BP3, human recombinant

4720-25
EUR 256

IGF-BP5, human recombinant

4723-100
EUR 620

IGF-BP5, human recombinant

4723-1000
EUR 3149

IGF-BP5, human recombinant

4723-25
EUR 256

IGF-BP2, human recombinant

7165-10
EUR 251

IGF-BP2, human recombinant

7165-50
EUR 936

IGF-BP7, human recombinant

7167-10
EUR 207

IGF-BP7, human recombinant

7167-50
EUR 675

IGF-BP6, human recombinant

7350-20
EUR 370

IGF-2/ Rat IGF- 2 ELISA Kit

ELA-E0051r 96 Tests
EUR 886

Anti-IGF1/Igf I Rabbit Monoclonal Antibody

M00148 100ug/vial
EUR 397
Description: Rabbit Monoclonal IGF1/Igf I Antibody. Validated in WB and tested in Human.

Anti-IGF2/Igf Ii Rabbit Monoclonal Antibody

M00335 100ug/vial
EUR 397
Description: Rabbit Monoclonal IGF2/Igf Ii Antibody. Validated in IF, WB and tested in Human.

Anti-Phospho-IGF-IR (Y1165/Y1166) antibody

STJ90299 200 µl
EUR 197
Description: Rabbit polyclonal to Phospho-IGF-IR (Y1165/Y1166).

Mouse Anti-Human IGF-1R monoclonal antibody, clone JID716

CABT-L2807-100uL500uL 100 uL, 500 uL
EUR 502

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-100ug

QP5264-100ug 100ug
EUR 363

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-10ug

QP5264-10ug 10ug
EUR 136

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-1mg

QP5264-1mg 1mg
EUR 1261

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-500ug

QP5264-500ug 500ug
EUR 762

Recombinant Human IGF-2/ IGF-II Protein, Untagged, E.coli-50ug

QP5264-50ug 50ug
EUR 237

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-100ug

QP8601-ec-100ug 100ug
EUR 408

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-10ug

QP8601-ec-10ug 10ug
EUR 200

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-1mg

QP8601-ec-1mg 1mg
EUR 1632

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-200ug

QP8601-ec-200ug 200ug
EUR 634

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-500ug

QP8601-ec-500ug 500ug
EUR 1060

Recombinant Human IGF-2/ IGF-II Protein, GST, E.coli-50ug

QP8601-ec-50ug 50ug
EUR 263

Recombinant Human IGF-BP7 Protein

PROTQ16270-2 25ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

Human IGF-I monoclonal antibody

MAM1 500 µg
EUR 299

Human IGF-II (Media Grade)

OM001 1 mg
EUR 902

Human IGF-II (Media Grade)

OU100 100 µg
EUR 327

Human IGF-II (Receptor Grade)

FM001 1 mg
EUR 161

Human IGF-II (Receptor Grade)

FU020 20 µg
EUR 299

Human IGF-II (Receptor Grade)

FU100 100 µg
EUR 392

Recombinant Human IGF-II Protein

PROTP01344-1 50ug
EUR 317
Description: The IGFs are mitogenic polypeptide growth factors that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar by structure and function to insulin, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but, IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions. Recombinant human IGF-I and IGF-II are globular proteins containing 70 and 67 amino acids, respectively, and 3 intra-molecular disulfide bonds.

Recombinant Human IGF-I Protein

PROTP05019-1 500ug
EUR 317
Description: The IGFs are mitogenic polypeptide growth factors that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar by structure and function to insulin, but have a much higher growth-promoting activity than insulin. IGF-II expression is influenced by placenta lactogen, while IGF-I expression is regulated by growth hormone. Both IGF-I and IGF-II signal through the tyrosine kinase type I receptor (IGF-IR), but, IGF-II can also signal through the IGF-II/Mannose-6-phosphate receptor. Mature IGFs are generated by proteolytic processing of inactive precursor proteins, which contain N-terminal and C-terminal propeptide regions. Recombinant human IGF-I and IGF-II are globular proteins containing 70 and 67 amino acids, respectively, and 3 intra-molecular disulfide bonds.

Recombinant Human IGF-BP1 Protein

PROTP08833-1 25ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4 kDa cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of 235 amino acid residues (Isoform A).

Recombinant Human IGF-BP3 Protein

PROTP17936-2 25ug
EUR 317
Description: IGF-BP3 is a 30 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals and it is also found in α-granules of platelets. In addition to its ability to modulate the activity of IGF-I and IGF-II, IGF-BP3 exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.

Recombinant Human IGF-BP2 Protein

PROTP18065 20ug
EUR 317
Description: IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

*Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom 

Background/purpose: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Sufferers and strategies: Sera and information from 79 sufferers had been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) had been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) had been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers had been assessed.

Outcomes: S100A9 ranges had been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations had been discovered between alarmin ranges and BVAS, FFS, and VDI.

Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.

Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków

 Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).

The sufferers had been two girls from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers offered with RP-ILD with none scientific options of myositis and succumbed to their sickness regardless of aggressive medical therapy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.

Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro 

Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, notably for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and scientific impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, may very well be a better option and negate the necessity for an in vivo efficiency check. These immunochemical strategies require at the least one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the excellent characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for improvement of an in vitro efficiency immunoassay.

We’ve assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to assist prior in vivo efficiency information that was obtainable for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to establish pairs of antibodies that may very well be deployed in a sandwich immunoassay format. Not all characterisation assessments offered proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay improvement.

Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych

Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic circumstances described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case stories and investigations relating to anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the scientific information of three anti-GAD65 antibody-positive sufferers to discover the range and scientific options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.

Strategies: The scientific information of a sequence of three sufferers optimistic for anti-GAD65 antibody had been retrospectively analyzed. GAD65 antibodies had been decided in serum and CSF utilizing a cell-based assay.

Outcomes: All three sufferers had been feminine, and the onset ages had been four years and 9 months, 6 years, and 16 years previous. Their scientific phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The scientific signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers obtained immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.

Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nevertheless, sufferers with limbic encephalitis typically have refractory epilepsy within the continual section and have a poor long-term final result.

NAP-2, CXCL7, human

RC312-18 2ug
EUR 104.38

NAP-2, CXCL7, rat

RC352-18 2ug
EUR 104.38

NAP-2/CXCL7, Human

HY-P7268 50ug
EUR 533

NAP-2/CXCL7, Rat

HY-P7269 50ug
EUR 533

CXCL7 ELISA KIT|Human

EF001450 96 Tests
EUR 689

Human CXCL7 ELISA Kit

LF-EK50893 1×96T
EUR 648

Mouse beta Thromboglobulin (CXCL7/bTG) CLIA Kit

20-abx491403
  • EUR 7973.00
  • EUR 4246.00
  • EUR 981.00
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human CXCL7 PicoKine ELISA Kit

EK0729 96 wells
EUR 425
Description: For quantitative detection of human CXCL7 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA).

Human CXCL7 Antibody (Biotin Conjugate)

32852-05121 150 ug
EUR 369

Human CXCL7 AssayMax ELISA Kit

EC2270-1 96 Well Plate
EUR 477

ELISA kit for Human CXCL7

EK5304 96 tests
EUR 553
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CXCL7 in samples from serum, plasma, tissue homogenates and other biological fluids.

Recombinant Human CXCL7/NAP-2 Protein

RP00829 10 μg
EUR 221

NAP-2/CXCL7 (CHO-expressed), Human

HY-P7267 50ug
EUR 497

ThymusChemokine‑1/CXCL7 (CHO-expressed), Rat

HY-P7301 10ug
EUR 291

Rat PPBP/CXCL7 PicoKine ELISA Kit

EK0731 96 wells
EUR 425
Description: For Quantitative Detection of rat CXCL7 in cell culture supernates, serum and plasma (heparin, EDTA).

Human CXCL7 AssayLite Antibody (FITC Conjugate)

32852-05141 150 ug
EUR 428

Human CXCL7 AssayLite Antibody (RPE Conjugate)

32852-05151 150 ug
EUR 428

Human CXCL7 AssayLite Antibody (APC Conjugate)

32852-05161 150 ug
EUR 428

Human CXCL7 AssayLite Antibody (PerCP Conjugate)

32852-05171 150 ug
EUR 471

Neutrophil Activating Protein-2 (CXCL7) Antibody

20-abx137035
  • EUR 356.00
  • EUR 523.00
  • 0.5 mg
  • 1 mg

Neutrophil Activating Protein-2 (CXCL7) Protein

20-abx261559
  • EUR 328.00
  • EUR 3418.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg

Neutrophil Activating Protein-2 (CXCL7) Protein

20-abx261561
  • EUR 328.00
  • EUR 3418.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg

Nori® Hamster CXCL7 ELISA Kit

GR172274 96-well
EUR 461

Nori Equine CXCL7/NAP2 ELISA Kit

GR106909 96-well
EUR 461

Nori® Canine CXCL7 ELISA Kit

GR115398 96-well
EUR 461

ELISA kit for Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)

E-EL-M1269 1 plate of 96 wells
EUR 534
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant

Recombinant Human Neutrophil Activating Protein-2 (CXCL7)

7-02059 2µg Ask for price

Recombinant Human Neutrophil Activating Protein-2 (CXCL7)

7-02060 10µg Ask for price

Recombinant Human Neutrophil Activating Protein-2 (CXCL7)

7-02061 1mg Ask for price

Recombinant Rat Neutrophil Activating Protein-2 (CXCL7)

7-02065 2µg Ask for price

Recombinant Rat Neutrophil Activating Protein-2 (CXCL7)

7-02066 10µg Ask for price

Recombinant Rat Neutrophil Activating Protein-2 (CXCL7)

7-02067 1mg Ask for price

Human CXCL7(Platelet basic protein) ELISA Kit

EH0007 96T
EUR 567.6
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 9.375pg/ml

Nori® Human CXCL7-NAP2 ELISA Kit

GR106282 96-well
EUR 461

Pig Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit

abx511493-96tests 96 tests
EUR 911

Neutrophil Activating Protein-2 (CXCL7), 95 a.a. Protein

20-abx260678
  • EUR 328.00
  • EUR 3418.00
  • EUR 230.00
  • 10 ug
  • 1 mg
  • 2 µg

Human Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit

abx252283-96tests 96 tests
EUR 668

Rat Platelet Basic Protein / CXCL7 (PPBP) ELISA Kit

abx255841-96tests 96 tests
EUR 668

Recombinant (E.Coli) Human Neutrophil Activating Protein-2 (CXCL7)

RP-1008 10 ug
EUR 286

Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a.

7-02062 2µg Ask for price

Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a.

7-02063 10µg Ask for price

Recombinant Human Neutrophil Activating Protein-2 (CXCL7), 95 a.a.

7-02064 1mg Ask for price

Human Thromboglobulin, Beta (bTG/PBP/CXCL7/NAP2) CLIA Kit

abx197774-96tests 96 tests
EUR 825

NAP-2 Neutrophil Activating Protein-2 Rat Recombinant Protein (CXCL7)

PROTQ99ME0 Regular: 10ug
EUR 317
Description: NAP-2 Rat Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 62 amino acids and having a molecular mass of 6.8kDa.;The NAP 2 is purified by proprietary chromatographic techniques.

Human CXCL7 EZ-Set™ ELISA Kit (DIY Antibody Pairs)

EZ0729 5 plates/kit
EUR 268
Description: For the development of sandwich ELISA kit to measure human CXCL7 in cell culture supernates, cell lysates, tissue homogenates, serum and plasma (heparin, EDTA).

ELISA kit for Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)

E-EL-H1007 1 plate of 96 wells
EUR 534
Description: A sandwich ELISA kit for quantitative measurement of Human ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Plasma

NAP-2 Neutrophil Activating Protein-2 Human Recombinant Protein (CXCL7)

PROTP02775 Regular: 10ug
EUR 317
Description: Neutrophil Activating Protein-2 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton. ;The NAP-2 is purified by proprietary chromatographic techniques.

ELISA kit for Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta)

E-EL-R1087 1 plate of 96 wells
EUR 534
Description: A sandwich ELISA kit for quantitative measurement of Rat ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug

QP10212-ec-100ug 100ug
EUR 988

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug

QP10212-ec-10ug 10ug
EUR 290

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug

QP10212-ec-250ug 250ug
EUR 1731

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug

QP10212-ec-2ug 2ug
EUR 154

Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-100ug

QP10285-ec-100ug 100ug
EUR 1178

Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-10ug

QP10285-ec-10ug 10ug
EUR 290

Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-250ug

QP10285-ec-250ug 250ug
EUR 2067

Recombinant Rat NAP-2/ PPBP/ CXCL7 Protein, Untagged, E.coli-2ug

QP10285-ec-2ug 2ug
EUR 154

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-100ug

QP8641-ec-100ug 100ug
EUR 408

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-10ug

QP8641-ec-10ug 10ug
EUR 200

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-1mg

QP8641-ec-1mg 1mg
EUR 1632

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-200ug

QP8641-ec-200ug 200ug
EUR 634

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-500ug

QP8641-ec-500ug 500ug
EUR 1060

Recombinant Human NAP-2/ PPBP/ CXCL7 Protein, GST, E.coli-50ug

QP8641-ec-50ug 50ug
EUR 263

Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2

C056-10ug 10ug
EUR 202
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2

C056-1mg 1mg
EUR 2283
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2

C056-500ug 500ug
EUR 1613
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Recombinant Human C-X-C Motif Chemokine 7/CXCL7/NAP-2

C056-50ug 50ug
EUR 496
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

NAP-2-95 Neutrophil Activating Protein-2 (CXCL7) Human Recombinant Protein, 95 a.a.

PROTP02775-1 Regular: 10ug
EUR 317
Description: NAP 2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 95 amino acids (35-128) and having a molecular mass of 10.3 kDa.;The NAP 2 is purified by proprietary chromatographic techniques.

Mouse Anti-FcεRIα

MOFCeRIaAP(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaAP(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaB(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaB(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaCFB(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaCFB(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaF(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaF(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaF(V500) 500 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPE(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPE(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPP(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPP(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPP55(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPP55(V25) 25 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPU(V100) 100 ug
EUR 50

Mouse Anti-FcεRIα

MOFCeRIaPU(V500) 500 ug
EUR 50

Mouse Anti-IL2

MOIL2A(V100) 100 ug
EUR 50

Mouse Anti-IL2

MOIL2A(V25) 25 ug
EUR 50

Mouse Anti-IL2

MOIL2B(V100) 100 ug
EUR 50

Mouse Anti-IL2

MOIL2B(V25) 25 ug
EUR 50

Mouse Anti-IL2

MOIL2CFB(V100) 100 ug
EUR 50

Mouse Anti-IL2

MOIL2CFB(V25) 25 ug
EUR 50

Dodaj komentarz

Twój adres e-mail nie zostanie opublikowany.